BLUE stock forecast
Our latest prediction for bluebird bio, Inc.'s stock price was made on the Jan. 7, 2020 when the stock price was at 90.19$.
In the short term (2weeks), BLUE's stock price should underperform the market by -5.68%. During that period the price should oscillate between -9.58% and +7.83%.
In the medium term (3months), BLUE's stock price should underperform the market by -11.47%. During that period the price should oscillate between -35.40% and +20.98%.Get email alerts
About bluebird bio, Inc.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
At the moment the company generates 54M USD in revenues.
On its last earning announcement, the company reported a loss of -13.00$ per share.
The book value per share is 26.91$
Three months stock forecastJan. 7, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|